These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7383233)

  • 1. Chronic clofibrate therapy in maintenance hemodialysis patients.
    Sherrard DJ; Goldberg AB; Haas LB; Brunzell JD
    Nephron; 1980; 25(5):219-21. PubMed ID: 7383233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.
    Goldberg AP; Applebaum-Bowden DM; Bierman EL; Hazzard WR; Haas LB; Sherrard DJ; Brunzell JD; Huttunen JK; Ehnholm C; Nikkila EA
    N Engl J Med; 1979 Nov; 301(20):1073-6. PubMed ID: 226883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low dose clofibrate in the treatment of hypertriglyceridemia in hemodialysis patients (author's transl)].
    Jarillo MD; Coca MC; Díaz Rubio C; Bello I; Gutiérrez-Millet V; Ruilope LM; Rodicio JL; Alvarez Ude F
    Med Clin (Barc); 1980 Nov; 75(8):334-7. PubMed ID: 7442334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of the change in the dose of Clofibrate Spofa and interruption of treatment on the lipid level of blood serum in persons with hyperlipemia].
    Cagánová A; Cagán S
    Bratisl Lek Listy; 1972 Jul; 58(1):66-78. PubMed ID: 5077942
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of clofibrate toxicity in uremic hypertriglyceridemia.
    Goldberg AP; Sherrard DJ; Haas LB; Brunzell JD
    Clin Pharmacol Ther; 1977 Mar; 21(3):317-25. PubMed ID: 837651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofibrate-induced muscle damage in patients with chronic renal failure.
    Pierides AM; Alvarez-Ude F; Kerr DN
    Lancet; 1975 Dec; 2(7948):1279-82. PubMed ID: 54800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man.
    Cohn K; Sakai FJ; Langston MF
    Am Heart J; 1975 May; 89(5):591-8. PubMed ID: 1091127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease.
    Oliver MF
    Adv Exp Med Biol; 1985; 183():225-40. PubMed ID: 3898747
    [No Abstract]   [Full Text] [Related]  

  • 10. Clofibrate and niacin in coronary heart disease.
    JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963
    [No Abstract]   [Full Text] [Related]  

  • 11. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis.
    Oda H; Yorioka N; Okushin S; Nishida Y; Kushihata S; Ito T; Yamakido M
    Nephron; 1997; 76(1):7-14. PubMed ID: 9171293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in the lipid profile of patients with chronic renal failure, treated with folic acid.
    de Gómez Dumm NT; Giammona AM; Touceda LA
    Int J Vitam Nutr Res; 2003 May; 73(3):215-20. PubMed ID: 12847999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Flaxseed Oil on Serum Lipids and Lipoproteins in Hemodialysis Patients: a Randomized Controlled Trial.
    Mirfatahi M; Tabibi H; Nasrollahi A; Hedayati M
    Iran J Kidney Dis; 2016 Nov; 10(6):405-412. PubMed ID: 27904000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of Clofibrat on plasma lipid levels.
    Szostak WB; Cybulska B; Ruzyllo E
    Mater Med Pol; 1971; 3(4):12-4. PubMed ID: 5162168
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy and prevention of arteriosclerosis].
    Gerö S
    Z Alternsforsch; 1971; 24(4):301-20. PubMed ID: 4110936
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients.
    Kooshki A; Taleban FA; Tabibi H; Hedayati M
    Ren Fail; 2011; 33(9):892-8. PubMed ID: 21859401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutral-lipid transfers and cholesteryl ester transfer protein in hemodialyzed patients.
    Reade V; Mezdour H; Reade R; Kandoussi M; Dracon M; Fruchart JC; Cachera C
    Am J Nephrol; 1996; 16(5):394-401. PubMed ID: 8886176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients.
    Elisaf M; Bairaktari E; Katopodis K; Pappas M; Sferopoulos G; Tzallas C; Tsolas O; Siamopoulos KC
    Am J Nephrol; 1998; 18(5):416-21. PubMed ID: 9730566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis.
    Ansari MR; Maheshwari N; Shaikh MA; Laghari MS; ; Lal K; Ahmed K
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):21-5. PubMed ID: 22237213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.